随着数百万美国人开始使用GLP-1类减重药，减重药厂商开始投入大量资金面向消费者进行直接的 营销。机构Bernstein分析数据显示，目前约有12%的美国人正在服用这类药物。 2026.02. 10 本文字数：878，阅读时长大约2分钟 作者 | 第一财经 钱童心 美国食品和药物管理局（FDA）日前向减重药司美格鲁肽厂商诺和诺德发出警告信，称该公司的口 服减重药电视广告带有误导性。 FDA的这封警告信正值减重药竞争加剧之际。诺和诺德、礼来等减重药厂商借今年的美国超级碗投 放了大量电视广告。 但诺和诺德称，FDA的最新警告不涉及超级碗广告，而是常规播放的关于司美格鲁肽口服减重药电 视广告。 去年年底，司美格鲁肽口服减重药获得美国FDA批准，成为全球首个获批上市的GLP-1类口服减重 药，早于竞争对手礼来。该药物于今年年初正式在美国上市销售，但尚未在中国上市销售。 在FDA的警告信中，监管机构认为，诺和诺德的电视广告误导性地暗示，与其他GLP-1类减重药相 比，司美股鲁肽口服减重药效果更佳。这种宣传违反了美国联邦食品、药品和化妆品法。FDA要求 诺和诺德立即采取行动解决这种违规行为，包括停止所有包含误导性信息的广 ...

FDA的这封警告信正值减重药竞争加剧之际。诺和诺德、礼来等减重药厂商借今年的美国超级碗投放了 大量电视广告。 美国食品和药物管理局（FDA）日前向减重药司美格鲁肽厂商诺和诺德发出警告信，称该公司的口服减 重药电视广告带有误导性。 FDA的这封警告信正值减重药竞争加剧之际。诺和诺德、礼来等减重药厂商借今年的美国超级碗投放了 大量电视广告。 但诺和诺德称，FDA的最新警告不涉及超级碗广告，而是常规播放的关于司美格鲁肽口服减重药电视广 告。 随着数百万美国人开始使用GLP-1类减重药，减重药厂商开始投入大量资金面向消费者进行直接的营 销。机构Bernstein分析数据显示，目前约有12%的美国人正在服用这类药物。 在FDA的警告信中，监管机构认为，诺和诺德的电视广告误导性地暗示，与其他GLP-1类减重药相比， 司美股鲁肽口服减重药效果更佳。这种宣传违反了美国联邦食品、药品和化妆品法。FDA要求诺和诺德 立即采取行动解决这种违规行为，包括停止所有包含误导性信息的广告。 FDA还指出，诺和诺德的广告暗示了司美格鲁肽减重药除了减重之外的益处，如情绪缓解、心理负担减 轻等，而这些好处尚未得到证明。 对此，诺和诺德回应称，将 ...

近日，诺和诺德宣布，减重版司美格鲁肽注射液(商品名：诺和盈)心血管适应症上市申请获得中国国家 药品监督管理局(NMPA)批准，适用于降低已确诊为心血管疾病且BMI≥27kg/m2成人患者的主要心血管 不良事件的风险，成为国内首个获批心血管适应症的GLP-1类减重药。 ...

（文章来源：第一财经） 12月22日，减重版司美格鲁肽注射液（商品名：诺和盈）心血管适应症上市申请获得中国国家药品监督 管理局（NMPA）批准，适用于降低已确诊为心血管疾病且BMI≥27kg/m2成人患者的主要心血管不良事 件的风险，成为国内首个获批心血管适应症的GLP-1类减重药。 ...

Core Viewpoint - Novo Nordisk's semaglutide (brand name: Wegovy) has received accelerated approval from the FDA for a new indication to treat metabolic dysfunction-associated steatotic liver disease (MASH), enhancing its position in the metabolic disease market [3][4]. Group 1: Company Developments - The FDA's approval marks semaglutide as the first and only GLP-1 drug officially approved for improving fatty liver [3]. - Novo Nordisk's recent studies indicate that semaglutide (2.4mg) combined with appropriate diet and exercise can significantly improve the condition of patients with fatty liver and moderate to severe liver fibrosis compared to a placebo [3][4]. Group 2: Industry Trends - Fatty liver has replaced viral hepatitis as the leading chronic liver disease in China, closely linked to obesity and diabetes, both of which are on the rise [4]. - A report published in The Lancet highlights a significant shift in the causes of liver cancer globally, with metabolic dysfunction-related fatty liver disease (MASLD) and MASH emerging as important contributors, accelerated by obesity and diabetes [4]. - The proportion of liver cancer cases related to MASH is projected to increase from 8% in 2022 to 11% by 2050, representing a 35% rise, particularly in developed countries [4].

Group 1 - GLP-1 drugs are gaining attention for their potential in treating fatty liver disease, with Novo Nordisk's semaglutide (brand name: Wegovy) recently receiving accelerated approval from the FDA for treating metabolic dysfunction-associated steatotic liver disease (MASH) [1] - Novo Nordisk's research indicates that semaglutide (2.4mg), combined with appropriate diet and exercise, can significantly improve the condition of patients with fatty liver and moderate to severe liver fibrosis compared to placebo [1] - This approval marks semaglutide as the first and only GLP-1 drug officially approved for improving fatty liver, and the second drug approved by the FDA for treating fatty liver, following Madrigal Pharmaceuticals' resmetirom [1] Group 2 - Fatty liver has become the leading chronic liver disease in China, surpassing viral hepatitis, with obesity and metabolic syndrome identified as primary causes of liver function abnormalities [2] - The prevalence of fatty liver is closely linked to obesity and diabetes, both of which are on the rise in China, suggesting an increasing trend in fatty liver cases [2] - A report published in The Lancet highlights that metabolic dysfunction-associated fatty liver disease (MASLD) and MASH are emerging as significant causes of liver cancer, with the proportion of liver cancer cases related to MASH expected to increase from 8% in 2022 to 11% by 2050, a 35% rise [2]

Core Insights - Multiple domestic GLP-1 weight loss drug developers are targeting overseas markets and have established several licensing agreements with multinational companies, indicating that competition for Chinese GLP-1 weight loss drugs will extend to the global market [1][5] - The U.S. market, known for its strong payment capabilities, is becoming a key focus for Chinese weight loss drug companies as they accelerate their research and development efforts [1][6] Industry Developments - Companies such as Heng Rui Medicine, Cheng Yi Biology, East China Medicine, Gan Li Pharmaceutical, and Hansoh Pharmaceutical have entered the GLP-1 weight loss drug market, including next-generation oral small molecule drugs [1] - Recent breakthroughs include the approval of the dual receptor agonist Masitide injection by the National Medical Products Administration (NMPA) for long-term weight control in adults, marking it as the only domestic GLP-1 weight loss drug competing with international giants [3][5] Clinical Progress - Several companies have reported positive clinical data, with Heng Rui Medicine and its U.S. partner Kailera Therapeutics announcing successful Phase III trial results for their GLP-1/GIP dual receptor agonist HRS9531, with plans to submit a New Drug Application (NDA) [4] - The drug Ecnoglutide developed by Xianweida has submitted an NDA for weight management and type 2 diabetes indications, although it has not yet been approved [4][6] Market Potential - The global GLP-1 drug market is projected to exceed $60 billion by 2025, with the Chinese market expected to reach 20 billion RMB, growing at over 28% annually [6] - The U.S. market presents significant opportunities, with high profit margins for weight loss drugs, despite the current dominance of two major players, Eli Lilly and Novo Nordisk [6][7] Patient Engagement - A recent survey indicated that 63% of U.S. patients continued using the weight loss drug Semaglutide after one year, highlighting the growing acceptance and adherence to GLP-1 medications [7] - The expansion of insurance coverage for these drugs is expected to further increase the patient population eligible for GLP-1 weight loss treatments [7]

Core Insights - The clinical study of the innovative weight-loss drug, Masitide, developed in China, has reached international leading status, potentially transforming clinical treatment and guidelines for overweight and obesity both domestically and internationally [1][4]. Group 1: Clinical Study Details - The study published in the New England Journal of Medicine (NEJM) is led by Professor Ji Linong from Peking University People's Hospital and is the first Phase III, double-blind, placebo-controlled trial (GLORY-1) assessing the efficacy and safety of Masitide in overweight or obese Chinese participants [1][4]. - The GLORY-1 trial set a weight loss target of 5%-15% within 3-6 months for overweight and mildly obese patients, with nearly half of the participants achieving a weight loss greater than 15% [4][5]. Group 2: Drug Development and Market Potential - Masitide is the world's first and only GCG/GLP-1 dual receptor agonist for weight loss and glycemic control, co-developed by Innovent Biologics and Eli Lilly, with commercialization rights in China secured in 2019 [4]. - The drug is expected to be approved for market in China this year, targeting both weight loss and glycemic control indications [4]. Group 3: Research Significance and Global Recognition - The publication of the GLORY-1 study in a prestigious journal signifies international recognition of China's innovative research in the field of endocrine metabolism [5]. - The study highlights the unique characteristics and treatment needs of the Chinese population regarding obesity, contrasting with existing guidelines primarily based on data from Caucasian populations [4][5]. Group 4: Comparative Efficacy - At 48 weeks of treatment, the proportion of participants achieving at least 15% weight loss in the 4mg and 6mg Masitide groups were 35.7% and 49.5%, respectively [5]. - In comparison, a recent head-to-head study of competing GLP-1 weight-loss drugs showed that 64.6% and 40.1% of patients achieved similar weight loss with alternative treatments [5].